# Ocular social jetlag: a driver of immune-metabolic dysfunction in dry eye disease

**Authors:** Yating Zhou, Yuliang Gu, Jian Yin, Tuo Jin

PMC · DOI: 10.3389/fimmu.2026.1771774 · Frontiers in Immunology · 2026-02-20

## TL;DR

This paper introduces the idea that modern lifestyle habits disrupt eye health by causing immune and metabolic issues linked to dry eye disease.

## Contribution

The paper introduces 'ocular social jetlag' as a novel concept linking circadian misalignment to dry eye disease.

## Key findings

- Ocular social jetlag disrupts peripheral ocular clocks and causes immune-metabolic reprogramming.
- This disruption leads to metabolic stress, oxidative amplification, and inflammasome activation before tissue damage occurs.
- Digital immune phenotyping and chronotherapeutic interventions are proposed for precision management of dry eye disease.

## Abstract

Dry eye disease (DED) is increasingly prevalent among young individuals and often exhibits severe symptoms despite minimal structural damage, challenging the traditional structure–inflammation paradigm. We propose the concept of ocular “social jetlag,” defined as chronic circadian misalignment imposed by modern lifestyles, as a key upstream driver of meibomian gland dysfunction and contemporary DED. We integrate emerging evidence to suggest that social jetlag disrupts peripheral ocular clocks, triggering immune–metabolic circadian reprogramming characterized by metabolic stress, loss of temporal immune gating, oxidative amplification, and inflammasome activation. This cascade precedes overt tissue damage and explains the mismatch between symptoms and structural findings. Viewing the ocular surface as a dynamic biosensor of systemic clock–immune–metabolism networks, we further highlight digital immune phenotyping and chronotherapeutic interventions as promising strategies for precision management. This framework reframes DED from a purely local disorder to a rhythm-driven systemic condition, opening new avenues for mechanism-based prevention and treatment.

## Full-text entities

- **Genes:** Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Nr1d2 (nuclear receptor subfamily 1, group D, member 2) [NCBI Gene 353187] {aka RVR, Rev-erb}, Clock (clock circadian regulator) [NCBI Gene 12753] {aka 5330400M04Rik, KAT13D}, LYZ (lysozyme) [NCBI Gene 4069] {aka AMYLD5, LYZF1, LZM}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Nr1d1 (nuclear receptor subfamily 1, group D, member 1) [NCBI Gene 217166] {aka A530070C09Rik}, Bmal1 (basic helix-loop-helix ARNT like 1) [NCBI Gene 11865] {aka Arnt3, Arntl, BMAL1b, MOP3, bHLHe5, bmal1b'}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Per3 (period circadian clock 3) [NCBI Gene 18628] {aka 2810049O06Rik, mPer3}, Fasn (fatty acid synthase) [NCBI Gene 14104] {aka A630082H08Rik, FAS}, Rora (RAR-related orphan receptor alpha) [NCBI Gene 19883] {aka 9530021D13Rik, Nr1f1, ROR1, ROR2, ROR3, nmf267}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Cgas (cyclic GMP-AMP synthase) [NCBI Gene 214763] {aka E330016A19Rik, Mb21d1}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, Per2 (period circadian clock 2) [NCBI Gene 18627] {aka mKIAA0347, mPer2}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Scd1 (stearoyl-Coenzyme A desaturase 1) [NCBI Gene 20249] {aka Scd, Scd-1, ab}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Muc4 (mucin 4) [NCBI Gene 140474] {aka 4933405I11Rik, Asgp}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874]
- **Diseases:** Dry eye disease (MESH:D015352), duct obstruction (MESH:D002779), immune (MESH:D007154), tear hyposecretion (MESH:D007018), Photophobia (MESH:D020795), epithelial (MESH:D009375), rheumatoid arthritis (MESH:D001172), ocular discomfort (MESH:D015817), prostatitis (MESH:D011472), Corneal nerve injury (MESH:D065306), hyperalgesia (MESH:D006930), systemic (MESH:D015619), meibomian gland atrophy (MESH:D000080343), SJL (OMIM:300082), sleep deprivation (MESH:D012892), ocular dryness (MESH:D014987), neuropathic pain (MESH:D009437), depression (MESH:D003866), Chronic pain (MESH:D059350), traumatic brain injury (MESH:D000070642), circadian disruption (MESH:D019958), atrophy (MESH:D001284), anxiety (MESH:D001007), irritation (MESH:D001523), ocular surface diseases (MESH:D010534), nonalcoholic steatohepatitis (MESH:D065626), Sjogren's syndrome (MESH:D012859), pain (MESH:D010146), mitochondrial dysfunction (MESH:D028361), corneal inflammation (MESH:D007249), fibrosis (MESH:D005355), metabolic syndrome (MESH:D024821), immunometabolic dysregulation (MESH:D021081), metabolic disease (MESH:D008659), lacrimal gland (MESH:C562407), mitochondrial structural abnormalities (MESH:C566527), clock dysregulation (MESH:C000719197), Hypoxic (MESH:D002534)
- **Chemicals:** saturated fatty acids (MESH:D005227), MOF (MESH:C037042), pilocarpine (MESH:D010862), ROS (-), melatonin (MESH:D008550), NAD+ (MESH:D009243), LPS (MESH:D008070), lipid (MESH:D008055), glutathione (MESH:D005978), hydrocortisone (MESH:D006854), SR9011 (MESH:C572450)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12962916/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12962916/full.md

## References

103 references — full list in the complete paper: https://tomesphere.com/paper/PMC12962916/full.md

---
Source: https://tomesphere.com/paper/PMC12962916